Eva Pharma
EVA Pharma is a multinational pharmaceutical company headquartered in Egypt with more than a century of corporate history. The company operates multiple manufacturing facilities and research centres in the Middle East and Africa, reports producing ~1,000,000 packs daily, maintains a portfolio of ~300 marketed products with several hundred more in development, and states capabilities across small-molecule and biologics manufacturing, clinical and pre-clinical research, and regional distribution and partnerships.
Industries
Nr. of Employees
Very Large (1000+)
Products
Apixaban (apixaban 5 mg) - anticoagulant product
Oral anticoagulant indicated for stroke and systemic embolism prevention in non-valvular atrial fibrillation, and treatment/prevention of DVT and PE.
Armodafinil (Armodafinil 50 mg) - wakefulness agent
Treatment of excessive sleepiness associated with obstructive sleep apnea, narcolepsy, or shift work sleep disorder.
Gabapentin (Gabapentin 300 mg) - neuropathic pain
Oral gabapentin product indicated for neuropathic pain.
Favipiravir (Favipiravir 200 mg) - antiviral
Antiviral oral formulation for treatment of certain influenza virus infections when other agents are ineffective.
Selected additional products (examples)
Examples from the product portfolio across therapeutic areas: etoricoxib for inflammatory conditions, perindopril+amlodipine for hypertension, fluticasone for allergic rhinitis, silodosin for BPH, L-carnitine formulations for deficiency states, alfacalcidol for calcium metabolism disorders.
Apixaban (apixaban 5 mg) - anticoagulant product
Oral anticoagulant indicated for stroke and systemic embolism prevention in non-valvular atrial fibrillation, and treatment/prevention of DVT and PE.
Armodafinil (Armodafinil 50 mg) - wakefulness agent
Treatment of excessive sleepiness associated with obstructive sleep apnea, narcolepsy, or shift work sleep disorder.
Gabapentin (Gabapentin 300 mg) - neuropathic pain
Oral gabapentin product indicated for neuropathic pain.
Favipiravir (Favipiravir 200 mg) - antiviral
Antiviral oral formulation for treatment of certain influenza virus infections when other agents are ineffective.
Selected additional products (examples)
Examples from the product portfolio across therapeutic areas: etoricoxib for inflammatory conditions, perindopril+amlodipine for hypertension, fluticasone for allergic rhinitis, silodosin for BPH, L-carnitine formulations for deficiency states, alfacalcidol for calcium metabolism disorders.
Services
Development and manufacturing services for pharmaceuticals and biologics provided from a dedicated development and manufacturing site.
In-house clinical and medical affairs capabilities to support pre-clinical and clinical programs, including investigator engagement and program management.
Development and manufacturing services for pharmaceuticals and biologics provided from a dedicated development and manufacturing site.
In-house clinical and medical affairs capabilities to support pre-clinical and clinical programs, including investigator engagement and program management.
Expertise Areas
- Large-scale pharmaceutical manufacturing
- Biologics manufacturing and scale-up
- Pre-clinical and clinical research
- Regulatory submissions and compliance
Key Technologies
- Biologics production (vials and cartridges)
- Oral solid dose and formulation manufacturing
- Sterile injectable manufacturing
- CDMO development platforms
News & Updates
Event appearance and participation.
Conference participation and opportunities to book meetings.
Exhibition and meeting bookings at CPHI Middle East.
Announcement of a marketing authorization for an ondansetron product in Canada.
News announcing a strategic partnership between the company and an international pharmaceutical company to support business and/or product access.
Multiple newsroom items covering conference participation and corporate campaigns.
Event appearance and participation.
Conference participation and opportunities to book meetings.
Exhibition and meeting bookings at CPHI Middle East.
Announcement of a marketing authorization for an ondansetron product in Canada.
News announcing a strategic partnership between the company and an international pharmaceutical company to support business and/or product access.
Multiple newsroom items covering conference participation and corporate campaigns.